Factor VIII preparations: need for prospective pharmacovigilance

This publication has 10 references indexed in Scilit:

• Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
  The Lancet, 1993
• Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate
  Blood, 1993
• A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group
  Blood, 1993
• Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors
  New England Journal of Medicine, 1993
• Modern Treatment of Hemophilia: From the Shadows Towards the Light
  Thrombosis and Haemostasis, 1993
• A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate
  Thrombosis and Haemostasis, 1993
• Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
  The Lancet, 1992
• Treatment of Hemophilia A with a Highly Purified Factor VIII Concentrate Prepared by Anti-FVIIIc Immunoaffinity Chromatography
  Thrombosis and Haemostasis, 1992
• The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate [see comments]
  Blood, 1991
• FACTOR VIII AND IX INHIBITORS AFTER EXPOSURE TO HEAT-TREATED CONCENTRATES
  The Lancet, 1987